This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

This study has been completed.
Sponsor:
Collaborator:
The EMMES Corporation
Information provided by (Responsible Party):
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT00621192
First received: February 20, 2008
Last updated: March 30, 2015
Last verified: March 2015
Results First Received: October 20, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Necrotizing Enterocolitis
Intra-abdominal Infection
Intervention: Drug: meropenem

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Enrollment Period - June 19, 2008 to October 6, 2009 Locations - Hospitals including University Hospitals Total number of sites - 24 Total number of participants - 200

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Other antimicrobials in addition to meropenem was used in the study due to concerns regarding the safety and ethics of using monotherapy in this patient population.The study was designed as an open-label, dose escalation study because sufficient data regarding the feasibility of a randomized, active controlled efficacy study was unavailable.

Reporting Groups
  Description
1. GA <32 Wks; PNA<2 Wks Group 1: GA at birth below 32 weeks - PNA < 2 weeks;
2. GA <32 Wks; PNA 91days ≥ 2Wks Group 2: GA at birth below 32 weeks - PNA ≥ 2 weeks and < 91 days
3. GA ≥ 32 Wks; PNA <2 Wks Group 3: GA at birth 32 weeks or older - PNA < 2 weeks;
4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks Group 4: GA at birth 32 weeks or older - PNA ≥ 2 weeks and < 91 days.

Participant Flow:   Overall Study
    1. GA <32 Wks; PNA<2 Wks   2. GA <32 Wks; PNA 91days ≥ 2Wks   3. GA ≥ 32 Wks; PNA <2 Wks   4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks
STARTED   39   103   31   27 
Safety Population   39   103   31   27 
Efficacy Population   39   101   28   27 
COMPLETED   35   94   26   24 
NOT COMPLETED   4   9   5   3 
Withdrawal by Subject                0                0                2                0 
Physician Decision                1                3                0                0 
Protocol Violation                1                0                0                1 
Adverse Event                0                1                0                1 
Death                2                5                0                0 
Final Assessments not Completed                0                0                3                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
1. GA <32 Wks; PNA<2 Wks Group 1: GA at birth below 32 weeks - PNA < 2 weeks;
2. GA <32 Wks; PNA 91days ≥ 2Wks Group 2: GA at birth below 32 weeks - PNA ≥ 2 weeks and < 91 days
3. GA ≥ 32 Wks; PNA <2 Wks Group 3: GA at birth 32 weeks or older - PNA < 2 weeks;
4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks Group 4: GA at birth 32 weeks or older - PNA ≥ 2 weeks and < 91 days.
Total Total of all reporting groups

Baseline Measures
   1. GA <32 Wks; PNA<2 Wks   2. GA <32 Wks; PNA 91days ≥ 2Wks   3. GA ≥ 32 Wks; PNA <2 Wks   4. GA ≥32 Wks; PNA 91 Days ≥ 2 Wks   Total 
Overall Participants Analyzed 
[Units: Participants]
 39   103   31   27   200 
Age [1] 
[Units: Days]
Mean (Standard Deviation)
         
Mean Postnatal Age   8.5  (3.3)   38.3  (19.3)   6.5  (3.5)   36.0  (22.0)   27.3  (21.6) 
[1] Post Natal Age
Gender 
[Units: Participants]
         
Female   15   47   9   11   82 
Male   24   56   22   16   118 
Ethnicity (NIH/OMB) 
[Units: Participants]
         
Hispanic or Latino   5   16   4   3   28 
Not Hispanic or Latino   32   81   27   24   164 
Unknown or Not Reported   2   6   0   0   8 
Race (NIH/OMB) 
[Units: Participants]
         
American Indian or Alaska Native   0   0   0   0   0 
Asian   0   1   0   1   2 
Native Hawaiian or Other Pacific Islander   1   0   1   0   2 
Black or African American   12   33   8   5   58 
White   25   65   21   18   129 
More than one race   1   2   0   2   5 
Unknown or Not Reported   0   2   1   1   4 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)   [ Time Frame: Average of 12 days (3 to 21 days) ]

2.  Primary:   Deaths   [ Time Frame: Up to 51 days (Recorded from the time of informed consent until 72 hours following the last dose of study drug) ]

3.  Primary:   Meropenem Clearance   [ Time Frame: Up to 7-8hrs post drug administration ]

4.  Primary:   Key Safety Endpoints   [ Time Frame: Up to 51 days (Adverse Events (AEs) were recorded from the time of informed consent until 72 hours following the last dose of study drug) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: David Siegel, MD
Organization: Eunice Kennedy Shriver National Institute of Child Health and Human Development
phone: 301-595-8670
e-mail: siegelda@mail.nih.gov


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier: NCT00621192     History of Changes
Other Study ID Numbers: HHSN267200700051C
HHSN267200700051C ( Other Identifier: NICHD )
Study First Received: February 20, 2008
Results First Received: October 20, 2011
Last Updated: March 30, 2015